Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: Ten-year analysis - An intergroup study

Journal of Clinical Oncology

Volumn 16, Issue 11, 1998, Pages 3486-3492

  Mansour, Edward G ^a   Gray, Robert ^a   Shatila, Ahmad H ^a   Tormey, Douglass C ^a   Cooper, M Robert ^a   Osborne, C Kent ^a   Falkson, Geoffrey ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PREDNISONE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MASTECTOMY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0031766681     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.11.3486     Document Type: Article

References (13)

1. Pearson OH, Hubay CA, Gordon NH, et al: Estrogen receptors and prognosis of breast cancer, in Hollander VP (ed): Hormonally Responsive Tumors. Orlando, FL, Academic, 1985, pp 487-503
2. McGuire WL: Prognostic factors in primary breast cancer. Cancer Sur 5:527-536, 1986
3. Mansour EG, Gray R, Shatila A, et al: Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. N Engl J Med 320:485-490, 1989
4. Mansour EG, Eudey L, Shatila AH, et al: Adjuvant therapy in node-negative breast cancer. Is it is necessary for all patients? An Intergroup study, in Salmon SE (ed): Adjuvant Therapy of Cancer, vol 6. Philadelphia, PA, Saunders, 1990; pp 174-189
5. Zelen M: The randomization and stratification of patients to clinical trials. J Chronic Dis 27:369-375, 1974
6. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
7. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc A 135:185-198, 1972
8. Dressier LG, Eudey L, Tormey DC, et al: Preliminary analysis of the impact of DNA flow cytometry measurements to predict time to recurrent in the intergroup (INT0011) node negative clinical trial: An Eastern Cooperative Oncology intergroup study. JNCI Monogr 11: 167-172, 1992
9. Clark GM, Mathieu MC, Owens MA, et al: Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol 10:428-432, 1992
10. Allred DC, Clark DC, Tandon AK, et al: HER-2/eu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605, 1992
11. Elledge RM, Gray R, Mansour E, et al: Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 87:1254-1256, 1995
12. Fisher B, Slack N, Katrych D, et al: Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 140: 528-524, 1975
13. Rosen PP, Groshen S, Saigo PR, et al: A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 7:355-366, 1989